Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition t...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positi...
Moody's Ratings (Moody's) downgraded ModivCare Inc.'s corporate family rating (CFR) to Ca from Caa1 and probability of default rating (PDR) to D-PD from Caa1-PD. At the same time, we downgraded the senior secured bank credit facility rating to Caa3 from B3, the senior secured second lien notes to C ...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available : About FLAMING...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more ...
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approv...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: Jun 28, 20...
Liberty Star’s Hay Mountain Project Shines Spotlight on Arizona Critical Minerals; DC Advocacy Accelerates Government Awareness TUCSON, AZ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () is proud to highlight the renewed national focus on its flagship Hay Mountain Project in Cochise County, Arizona—a property now recognized as a cornerstone for America’s critical mineral ambitions. This builds on a surge of exploration momentum and a successful Washington, DC advocacy campaign in May led by Board Chairman Pete O’Heeron. Congressional Support: Gosar’s Letter to Cabi...
Liberty Star Embarks on 3D IP Survey at Red Rock Gold Project, SE Arizona TUCSON, AZ, June 30, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () is pleased to announce the launch of a state-of-the-art 3D induced polarization survey (“3D IP Survey,” “Survey”) at its wholly owned Red Rock Canyon Gold Project (RRC), part of the Hay Mountain Project in southeast Arizona. The Survey aims to be the next initiative to unlock the immense potential of RRC, which is believed to host commercially significant metals associated with epithermal gold mineralization, a hallmark of the minera...
Liberty Star Announces Successful SAM Registration, Enhancing Opportunities for Federal Grants TUCSON, AZ, June 02, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals (OTCQB: LBSR), a U.S.-based exploration company focused on strategically vital critical minerals, announced today its successful registration with the System for Award Management (SAM), the federal government’s central platform for contract and grant eligibility. This isn’t just a check-the-box achievement—it’s a strategic move that expands our access to federal funding opportunities, positioning Liberty Star to contribute dire...
Lockout Rally in Full Swing Continuing the trend from last week's U.S. Macro Vision (4/29/25), we are seeing more and more signs that lead us to believe the S&P 500 (SPX) made a major bottom at 4800-4820, which is where we initially discussed in our 4/8/25 Compass to look for a local bottom to develop. As a result, we have been short-term bullish since our 4/22/25 Compass, when we noted that the SPX was testing 5100-5120 support, a potential bounce spot and a level to trade long against. With t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.